Annexon, Inc. ANNX
Super Investor & Insider
1
Fondi che lo detengono
#1446
Rank consenso
1.4%
% dei portafogli
$388,642
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Polen Capital Management · Polen Capital Management | 0% | Buy | 70,152 | $388,642 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for autoimmune, neurodegenerative, and ophthalmic diseases. The company advances a pipeline of product candidates designed to target the classical complement pathway, a key component of the immune system impli…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees93
TickerANNX
Statistics
Market Cap$784.1M
Revenue (TTM)$0
Net Income-$206.7M
Net Margin—
EPS$-1.34
P/E-3.52
P/S—
P/B3.73
EV/EBITDA-2.81
ROE-87.6%
Dividend Yield—
Price$4.83
Data: Twelve Data · Revenue = mcap / P/S